ArticleNanomaterials (Basel, Switzerland)2020
Surface-Enhanced Raman Scattering and Fluorescence on Gold Nanogratings.
Article in Nanomaterials (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Exosomes in ovarian cancer: Impact on drug resistance and advances in SERS detection techniques.Journal of pharmaceutical analysis · 2025Review
- High-sensitivity qPCR detection method based on silver flower-like LSPR-active material.Scientific reports · 2025Article
- Principles and Applications of Resonance Energy Transfer Involving Noble Metallic Nanoparticles.Materials (Basel, Switzerland) · 2023Review
- Rapid Determination of the 'Legal Highs' 4-MMC and 4-MEC by Spectroelectrochemistry: Simultaneous Cyclic Voltammetry and In Situ Surface-Enhanced Raman Spectroscopy.Sensors (Basel, Switzerland) · 2021Article
- A Nanoplasmonic-Based Biosensing Approach for Wide-Range and Highly Sensitive Detection of Chemicals.Nanomaterials (Basel, Switzerland) · 2021Article
- Application of Novel Plasmonic Nanomaterials on SERS.Nanomaterials (Basel, Switzerland) · 2020Article
- Selectively enhanced Raman/fluorescence spectra in photonic-plasmonic hybrid structures.Nanoscale advances · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Surface-enhanced Raman scattering (SERS) spectroscopy is a sensitive sensing technique. It is desirable to have an easy method to produce SERS-active substrate with reproducible and robust signals. We propose a simple method to fabricate SERS-active substrates with high structural homogeneity and signal reproducibility using electron beam (E-beam) lithography without the problematic photoresist (PR) lift-off process. The substrate was fabricated by using E-beam to define nanograting patterns on the photoresist and subsequently coat a layer of gold thin film on top of it. Efficient and stable SERS signals were observed on the substrates. In order to investigate the enhancement mechanism, we compared the signals from this substrate with those with photoresist lifted-off, which are essentially discontinuous gold stripes. While both structures showed significant grating-period-dependent fluorescence enhancement, no SERS signal was observed on the photoresist lifted-off gratings. Only transverse magnetic (TM)-polarized excitation exhibited strong enhancement, which revealed its plasmonic attribution. The fluorescence enhancement showed distinct periodic dependence for the two structures, which is due to the different enhancement mechanism. We demonstrate using this substrate for specific protein binding detection. Similar periodicity dependence was observed. Detailed theoretical and experimental studies were performed to investigate the observed phenomena. We conclude that the excitation of surface plasmon polaritons on the continuous gold thin film is essential for the stable and efficient SERS effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.